current TNFi biologic (Table 3 5 In patients with active PsA despite treatment with TNFi biologic monotherapy, an IL-17i biologic is recommended over an IL-12/23i biologic, abatacept, or tofacitinib, and an IL-12/23i biologic is recommended over abatacept or tofacitinib. An IL-12/23i biologic may be considered instead of an IL-17i biologic if the patient has IBD or desires less frequent drug administration. Abatacept may be considered instead of an IL-17i or IL- Recommendations for the treatment of patients with active psoriatic arthritis (PsA) despite treatment with oral small molecules (OSMs). All recommendations are conditional based on low-to very-low-quality evidence. A conditional recommendation means that the panel believed the desirable effects of following the recommendation probably outweigh the undesirable effects, so the course of action would apply to the majority of the patients, but some may not want to follow the recommendation. Because of this, conditional